Breast cancer is the disease characterized by abnormal growth of cells in the breast tissue. Breast biopsy devices are used to diagnose breast cancer by removal of the sample from the breast tissue for laboratory testing. The breast biopsy is preferred when the formation of lumps in the breast or abnormal change in nipples such as congealing, scaling, cellulite, or crusting of the skin. Various types of breast biopsy devices are preferred for the breast cancer diagnosis such as vacuum-powered biopsy, fine-needle aspiration, and core needle biopsy among others.
Breast Biopsy Devices Market Drivers and Restrains
Increase in the global breast cancer prevalence rate, changes in lifestyle such as consumption of tobacco, alcohol and food habits, growing in the female population with hormonal imbalance, an increase in the breast cancer screening programs around the globe are anticipated to fuel the market over the forecast period. In addition, technological advancements with minimally invasive or non-invasive diagnostic procedure, favourable reimbursement policies, and rising investment by the companies for R&D activities are expected to boost the market. However, stringent regulatory guidelines, infections associated with the breast biopsy devices, and the high cost of the procedures are dampening the growth of the Market.
Breast biopsy devices market is growing at a significant CAGR over the forecast period. The breast biopsy is mandatory for the diagnosis of breast cancer which cannot be confirmed by breast mammograms. Increase in the global breast cancer incidences (according to World Cancer Research Fund International, about 1.7 Mn new cases were observed in 2012) propels the breast cancer devices market over the forecast period. Acquisitions and mergers, collaborations, patent approvals, and technological advancements are the key strategies followed by the companies for increasing their revenue in the market. For instance, in 2014, Leica Biosystems (Danaher Corporation) acquired Devicor Medical Products for strengthening its breast biopsy devices portfolio. Moreover, In January 2015, Intact Medical Corporation received FDA approval for the minimally-invasive breast biopsy device. In addition, fundraising by start-up companies for the innovation of novel devices also propels the market over the forecast period.
Breast biopsy devices market segmented based on device type, procedure type, guidance type, and end user
Based on the device type, the market is segmented into the following:
Based on the procedure type, the market is segmented into the following:
- Core needle biopsy
- Vacuum-assisted core biopsy
- Fine needle aspiration biopsy
- Stereotactic core needle biopsy
- Surgical biopsy
Based on guidance type, the market is segmented into the following:
- Ultrasound-guided biopsy
- Magnetic resonance imaging (MRI) guided biopsy
- Mammography guided stereotactic guided biopsy
Based on the end user, the market is segmented into the following:
- Ambulatory surgical centres
Geographically, breast biopsy devices market is segmented into Europe, Latin America, North America, Middle East & Africa, and Asia Pacific. North America has a lucrative growth in market owing to increase in the prevalence of breast cancer (according to Centre for Disease Control and Prevention 2014, about 236,968 women and 2,141 men were diagnosed with breast cancer in U.S.), technological advancements, and increase in healthcare expenditure in the region. Europe has a significant share owing to rise in prevalence of breast cancer majorly in Italy, Greece, Finland, Germany, and Netherlands where the prevalence rate is approximately more than 400 per 100,000 population. In addition, high adoption of novel technologies, development in healthcare infrastructure, changes in lifestyle, and government initiations to create awareness about breast cancer diagnosis programs are anticipated to fuel the market. Asia Pacific is an emerging region due to rise in female geriatric population majorly in Japan, China, and India. Moreover, increase in per capita income, rise in awareness about the breast cancer diagnosis, and rise in R&D for developing the minimally invasive procedures are driving the market.
Breast biopsy devices market leaders are Medtronic, Inc. (Ireland), Becton, Dickinson and Company (U.S.), Hologic Inc. (U.S.), C.R. Bard, Inc. (U.S.), Planmed Oy (Finland), Scion Medical Technologies, LLC (U.S.), and Leica Biosystems (Danaher Corporation) to name a few.
- In August 2017, Hologic has launched Brevera breast biopsy system for the real-time breast biopsy and verification
- The report provides granular level information about the market size, regional market share, and forecast from 2018-2024
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario